Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.16)
# 417
Out of 5,149 analysts
519
Total ratings
47.85%
Success rate
15.44%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Neutral | $11 → $10 | $10.67 | -6.28% | 18 | Mar 4, 2026 | |
| TBPH Theravance Biopharma | Maintains: Buy | $27 → $15 | $13.96 | +7.45% | 18 | Mar 4, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $33 → $34 | $27.85 | +22.08% | 24 | Mar 4, 2026 | |
| ARGX argenx SE | Maintains: Buy | $915 → $940 | $748.72 | +25.55% | 42 | Feb 27, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $34 | $23.60 | +44.07% | 5 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $45 → $48 | $20.16 | +138.10% | 28 | Feb 25, 2026 | |
| OTLK Outlook Therapeutics | Reiterates: Neutral | $0.5 | $0.42 | +18.60% | 20 | Feb 18, 2026 | |
| IMVT Immunovant | Reiterates: Buy | $35 | $26.71 | +31.04% | 24 | Feb 10, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $13 | $4.13 | +214.77% | 30 | Feb 3, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $340 → $1,245 | $318.22 | +291.24% | 31 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $117 | $91.30 | +28.15% | 36 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $22.10 | +71.95% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $5 | $3.09 | +61.81% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $40 | $27.85 | +43.63% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.57 | +666.77% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4 | $6.86 | -41.69% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $3.25 | +392.31% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $29.20 | +57.53% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.06 | +128.76% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $64.36 | +83.34% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $40.12 | +101.89% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $43.79 | +21.03% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.65 | +324.24% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $29.32 | +15.96% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.06 | +488.24% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.09 | +32,927.52% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.26 | +343.44% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $108.70 | +67.43% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.81 | +140.08% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $52.27 | -65.56% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $32.28 | -75.22% | 7 | Jun 11, 2019 |
Biohaven
Mar 4, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $10.67
Upside: -6.28%
Theravance Biopharma
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $15
Current: $13.96
Upside: +7.45%
Roivant Sciences
Mar 4, 2026
Maintains: Buy
Price Target: $33 → $34
Current: $27.85
Upside: +22.08%
argenx SE
Feb 27, 2026
Maintains: Buy
Price Target: $915 → $940
Current: $748.72
Upside: +25.55%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $34
Current: $23.60
Upside: +44.07%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $45 → $48
Current: $20.16
Upside: +138.10%
Outlook Therapeutics
Feb 18, 2026
Reiterates: Neutral
Price Target: $0.5
Current: $0.42
Upside: +18.60%
Immunovant
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $26.71
Upside: +31.04%
Evolus
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $4.13
Upside: +214.77%
Praxis Precision Medicines
Jan 30, 2026
Maintains: Buy
Price Target: $340 → $1,245
Current: $318.22
Upside: +291.24%
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $91.30
Upside: +28.15%
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $22.10
Upside: +71.95%
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.09
Upside: +61.81%
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $27.85
Upside: +43.63%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.57
Upside: +666.77%
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $6.86
Upside: -41.69%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $3.25
Upside: +392.31%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $29.20
Upside: +57.53%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.06
Upside: +128.76%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $64.36
Upside: +83.34%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $40.12
Upside: +101.89%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $43.79
Upside: +21.03%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.65
Upside: +324.24%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $29.32
Upside: +15.96%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $3.06
Upside: +488.24%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.09
Upside: +32,927.52%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.26
Upside: +343.44%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $108.70
Upside: +67.43%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.81
Upside: +140.08%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $52.27
Upside: -65.56%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $32.28
Upside: -75.22%